MRP8/ABCC11 Expression Is Regulated by Dexamethasone in Breast Cancer Cells and Is Associated to Progesterone Receptor Status in Breast Tumors

Author:

Honorat Mylène123,Mesnier Aurélia123,Vendrell Julie123,Di Pietro Attilio4,Lin Valérie5,Dumontet Charles123,Cohen Pascale123,Payen Léa12367

Affiliation:

1. Université de Lyon, Lyon1, Lyon 69008, France

2. Inserm, U590, Lyon 69008, France

3. Centre Léon Bérard, FNCLCC, Lyon 69008, France

4. Equipe Labellisée Ligue 2009, Institut de Biologie et Chimie des Protéines FR 3302, BM2SI, UMR 5086/Université Lyon 1, IFR128 BioSciences Gerland, 69367 Lyon Cedex 07, France

5. School of Biological Sciences, Nanyang Technological University, Singapore 637616

6. Laboratoire de Toxicologie, Faculté de Pharmacie, ISPB, Université de Lyon, Lyon 69008, France

7. Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Laboratoire de biochimie, 69495 Pierre-Bénite, France

Abstract

The ATP-binding cassette multidrug resistance protein 8 (MRP8/ABCC11) mediates the excretion of anticancer drugs. ABCC11 mRNA and protein levels were enhanced by DEX (dexamethasone) and by PROG (progesterone) in MCF7 (progesterone receptor-(PR-) positive) but not in MDA-MB-231 (PR-negative) breast cancer cells. This suggested a PR-signaling pathway involvement in ABCC11 regulation. Nevertheless, pregnenolone-16α-carbonitrile (GR antagonist) and clotrimazole strongly and moderately decreased ABCC11 expression levels in Glucocortocoid Receptor-(GR-) and Pregnane X Receptor (PXR)-positive MCF7 cells but not in MDA-MB-231 cells (GR- and PXR-positive). Thus, GR-signaling pathway involvement could not be excluded in ABCC11 regulation in MCF7 cells. Furthermore, ABCC11 levels were positively correlated with the PR status of postmenopausal patient breast tumors from two independent cohorts. Thus, in the subclass of breast tumors (Estrogen Receptor-(ER-) negative/PR-positive), the elevated expression level of ABCC11 may alter the sensitivity to ABCC11 anticancer substrates, especially under treatment combinations with DEX.

Funder

Institut national de la santé et de la recherche médicale

Publisher

Hindawi Limited

Subject

Cancer Research,Pharmacology (medical),Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3